HOME > Our Business > Self-Medication > Overseas Business

Overseas Business

Launching various products overseas for consumers around the world striving to be healthy.

Since acquiring the Asian OTC drug business of U.S.-based Bristol-Myers Squibb Company in 2009, we have continued to expand our overseas OTC drug business platform with acquisitions in Malaysia (Hoepharma) and Mexico (four companies including CICSA) and the restructuring of the existing joint venture in Thailand with Osotspa Co., Ltd. Total sales from the overseas OTC business (OTC drugs and energy drinks) in fiscal 2012 increased 31.3% in yearon- year terms to ¥17.6 billion, reflecting market growth and aggressive promotional activities.

 In the next stage of business development, we plan to increase sales of acquired brands and develop systems to leverage the business platform created. In April 2013, the business division responsible for overseas operations was transferred from Taisho Pharmaceutical to the Company to speed up handling of regulatory matters in each country while strengthening product development and the oversight of human resources management in each country.